The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Feeling stuffy and ready to reach for NyQuil, Benadryl, or Sudafed PE? Not so fast. The Food and Drug Administration (FDA) has proposed ending the use of oral phenylephrine, a common ingredient found ...

While allergies in domesticated animals like dogs, cats, horses, and some birds are common, experts say there are few ...

Here are five common over-the-counter drugs you should avoid when breastfeeding: The average adult experiences around two or ...

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product revenue for neffy sales, which reflects revenues from only one week following ...

The Nasal Drug Delivery Technology Market is driven by the rising demand for non-invasive administration methods that enhance patient compliance and bioavailability. Innovations such as advanced ...

Phenylephrine is included in many cold and flu products, but a scientific panel last year found that it doesn't really do its ...

Dealing with allergies is a lot like having a song stuck in your head that you didn’t want—yet here you are, enduring it.